WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Review Journal for Medical Science and Pharma Professionals
World Journal of Advance Healthcare Research (WJAHR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , Cosmos Impact Factor , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , IFSIJ Measure of Journal Quality , Scientific Journal Impact Factor (SJIF) , International Scientific Indexing, UAE (ISI) (Under Process) , International Impact Factor Services (IIFS) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , 

ISSN 2457-0400

Impact Factor  :  5.464

News & Updation

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in WJAHR coming Issue.

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • 6th International Conference on Human and Soci

    Venue:FCT Education Resource Center, Abuja- Nigeria                                        September 22-24, 2019

  • WJAHR New Impact Factor

    Its our Pleasure to Inform you that WJAHR Impact Factor has been increased from  4.897 to 5.464 due to high quality Publication at International Level

  • .

    6th INTERNATIONAL CONFERENCE ON EDUCATIONAL TECHNOLOGY AND CURRICULUM STUDIES(ICETC2019) 

     

    Venue: FCT Education Resource Center, Abuja-Nigeria

    September 22-24, 2019

  • New Issue Published

    Its Our pleasure to inform you that, WJAHR September 2023 Issue has been Published, Kindly check it on https://www.wjahr.com/home/current_issues

  • WJAHR: SEPTEMBER ISSUE PUBLISHED

    SEPTEMBER 2023 Issue has been successfully launched on 1 SEPTEMBER 2023.

Best Paper Awards

World Journal of Advance Healthcare Research (WJAHR)Honored the authors with best paper award, monthly based on the innovation of research work. Best paper will be selected by our expert panel.

Best Article of current issue

Download Article : Click here

Indexing

Abstract

ANTIHYPERTENSIVE AND ELECTROLYTE MODULATORY POTENTIAL OF VERNONIOSIDE E (STEROIDAL SAPONIN) FROM VERNONIA AMYGDALINA (ASTERECEA) IN ADULT ALBINO WISTAR RATS

*Igile G. O., Iwara A. I., Ekpe O. O., Isika A. I. and Mgbeje B. I. A.

ABSTRACT

Western lifestyle, urban diets and physical inactivity among urban dwellers in Nigeria have caused increase in incidences of hypertension among people of 40 years and above. Drugs for its treatment are expensive, while ethnopharmacology seem to provide alternative and cheaper options. Aqueous leaf extracts of Vernonia amygdalina (Bitter leaf) has been successfully used for centuries in Nigeria to treat hypertension, other cardiovascular diseases, stomach pains, fever and malaria. The present study evaluates the antihypertensive potential of Vernonioside E (VE) and crude extract (CE) of Vernonia amygdalina leaf, and the efficacy of VE and CE in reversing serum electrolyte concentrations, lipid/cholesterol, and enzyme activities implicated in the aetiology and manifestation of hypertension using Albino Wistar rats previously induced with 40mg/Kg bw hypertensive agent (N?-Nitro-L-arginine methyl ester hydrochloride, L-NAME) as study model. The LD50 of VE was also determined, while LD50 of CE has been previously determined and known. The LD50 of VE was determined to be 0.70 mg/kg. Vernonioside E (105.25± 2.29 mEq/L), the crude extract (108.55± 2.41 mEq/L) and Captopril (112.99± 2.30 mEq/L) produced significant (p<0.05) decreases in serum sodium concentration, when compared to the hypertensive control (165.72±15.05 mEq/L). The chloride levels in treated groups were slightly decreased while the potassium level was slightly increased compared to control groups. There was significant (p<0.05) decrease in total cholesterol levels in treatment groups, VE (56.14±2.15mg/kg), CE (57.40±2.20mg/kg) and Captopril (61.44±0.25mg/kg) compared to hypertensive control (77.63±2.97mg/kg). There were significant (P<0.05) decreases in triacylglycerol, low density lipoprotein (LDL), and very low density lipoprotein (VLDL) concentrations of treated groups when compared to hypertensive control. Also, there was significant (p<0.05) elevation of high density lipoprotein (HDL) concentration in treated and normal control groups when compared to hypertensive control. There was a significant (p<0.05) elevation of two key serum enzymes (AST and ALT) concentraions. It was concluded that, the biochemical changes observed suggests that Vernonioside E (VE) and crude extract (CE) of Vernonia amygdalina leaf are potential antihypertensive agents, and this confirms the ethnopharmacological claims of the use of aqueous extracts of the leaves of this plant in the treatment of high blood pressure and associated cardiovascular diseases.

[Full Text Article]